Literature DB >> 15076823

Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer.

Vickie L Shavers1, Martin Brown, Carrie N Klabunde, Arnold L Potosky, William Davis, Judd Moul, Angela Fahey.   

Abstract

BACKGROUND: Previous studies have found that racial/ethnic minority patients with prostate cancer are more frequently managed with "watchful waiting." Little, however, is known about the medical care received among men managed with watchful waiting. We examine the type and intensity of medical monitoring received by African American, Hispanic, and white patients with prostate cancer managed with "watchful waiting" in fee-for-service systems.
METHODS: Surveillance Epidemiology and End Results-Medicare data for men diagnosed with prostate cancer 1994-1996 were used in this study. Men were determined to have initially received watchful waiting if they did not receive surgery, radiation, or hormone treatment within the first 7 months of diagnosis. Crosstabulations, multivariate logistic, and Cox regressions were used to examine the association between clinical and sociodemographic variables and the receipt of a primary care, urology visit, prostate-specific antigen test, or bone scan.
RESULTS: In general, Hispanic and African American men received less medical monitoring and had longer median times from diagnosis to receipt of a medical monitoring visit or procedure than white men. Furthermore, nearly 6% of African American, 5% of Hispanic, and 1% of white men did not have any medical monitoring visits or procedures during the 60-month follow-up period (P<0.001). Differences in observed clinical or sociodemographic characteristics did not explain variations in medical monitoring.
CONCLUSION: Regular medical monitoring is considered by most medical authorities to be a necessary component of management with watchful waiting. The disproportionately low receipt of medical monitoring visits and procedures observed for African American and Hispanic men managed with watchful waiting in this study suggest that there are racial/ethnic disparities in the receipt of appropriate prostate cancer management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076823     DOI: 10.1097/01.mlr.0000117361.61444.71

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  27 in total

Review 1.  Comorbid disease and cancer: the need for more relevant conceptual models in health services research.

Authors:  Jane M Geraci; Carmen P Escalante; Jean L Freeman; James S Goodwin
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

2.  Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.

Authors:  April P Carson; Daniel L Howard; William R Carpenter; Yhenneko J Taylor; Sharon Peacock; Anna P Schenck; Paul A Godley
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

Review 3.  Prostate cancer epidemiology in the United States.

Authors:  Otis W Brawley
Journal:  World J Urol       Date:  2012-04-05       Impact factor: 4.226

4.  Treatment decisions for localized prostate cancer: a concept mapping approach.

Authors:  Stephanie L McFall; Patricia D Mullen; Theresa L Byrd; Scott B Cantor; Yen-Chi Le; Isabel Torres-Vigil; Curtis Pettaway; Robert J Volk
Journal:  Health Expect       Date:  2014-02-09       Impact factor: 3.377

5.  Trends in prostate cancer in the United States.

Authors:  Otis W Brawley
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

6.  Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urology       Date:  2016-09-22       Impact factor: 2.649

7.  Race, healthcare access and physician trust among prostate cancer patients.

Authors:  Young Kyung Do; William R Carpenter; Pamela Spain; Jack A Clark; Robert J Hamilton; Joseph A Galanko; Anne Jackman; James A Talcott; Paul A Godley
Journal:  Cancer Causes Control       Date:  2009-09-24       Impact factor: 2.506

8.  Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey.

Authors:  Georgios Lyratzopoulos; Josephine M Barbiere; David C Greenberg; Karen A Wright; David E Neal
Journal:  BMJ       Date:  2010-04-21

9.  Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.

Authors:  Hong Xiao; Fei Tan; Pierre Goovaerts; Askal Ali; Georges Adunlin; Clement K Gwede; Youjie Huang
Journal:  Am J Mens Health       Date:  2013-12-01

10.  Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study.

Authors:  S Evans; C Metcalfe; B Patel; F Ibrahim; K Anson; F Chinegwundoh; C Corbishley; D Gillatt; R Kirby; G Muir; V Nargund; R Popert; P Wilson; R Persad; Y Ben-Shlomo
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.